Zevra Homepage.
icon news News icon investors Investors icon careers Careers icon contact Contacts
  • About Us dropdown arrow dropdown arrow mobile
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
    • What We Do
    • Partnering
  • Patients & Caregivers dropdown arrow dropdown arrow mobile
    • Clinical Trials
    • Expanded Access Policy
    • Niemann-Pick Disease Type C
    • Urea Cycle Disorders
    • Vascular Ehlers-Danlos
    • Sleep Disorders
  • Our Products
    • MIPLYFFA®
    • OLPRUVA®
    • AZSTARYS®
  • Our Pipeline dropdown arrow dropdown arrow mobile
    • Pipeline
    • Clinical Trials
    • Publications & Presentations
    • Medical Literature
    • Medical Information
    • Investigator-Initiated Studies
  • News
  • Investors
  • Careers
  • Contacts

2019-2018

Home > 2019-2018

Single- and Multiple-dose Pharmacokinetics of KP415, a Novel d-Methylphenidate Product Containing a Prodrug of d-Methylphenidate, in Healthy Volunteers

January 26, 2023

Dose-finding Study of Abuse-Related Effects of Intranasal d-Methylphenidate in Recreational Stimulant Abusers

Human Abuse Potential of Intravenous Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers

Assessment of the Intravenous Abuse Potential Of Serdexmethylphenidate (SDX), a Novel, Investigational Prodrug of D-Methylphenidate: Evidence from Nonclinical and Clinical Studies

Human Abuse Potential of Intranasal Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, in Recreational Stimulant Abusers

Human Abuse Potential of Oral Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate, Compared to Focalin® XR and Phentermine in Recreational Stimulant Abusers

Dose-Proportionality and Steady-State Pharmacokinetics of KP415, an Investigational ADHD Product Containing Serdexmethylphenidate (SDX), a Novel Prodrug of d-Methylphenidate

Single-dose Pharmacokinetics of KP415, an Investigational Product Containing the Prodrug Serdexmethylphenidate (SDX), in Children and Adolescents with ADHD

Effect of Food and Alternative Dosing Methods on the Pharmacokinetics of KP415, an Investigational ADHD Product Containing the Prodrug, Serdexmethylphenidate (SDX)

Prodrugs for ADHD Treatments: Opportunities & Potential to Fill Unmet Medical Needs

January 25, 2023

About Us
Our Mission & Vision The Zevra Story Leadership Board of Directors What We Do Partnering
Patients & Caregiver
Clinical Trials Expanded Access Policy Niemann-Pick Disease Type C Urea Cycle Disorders Vascular Ehlers-Danlos Sleep Disorders
Our Products
MIPLYFFA® OLPRUVA® AZSTARYS®
Our Pipeline
Pipeline Clinical Trials Publications & Presentations Medical Literature Medical Information Investigator-Initiated Studies
Careers
Culture Job Openings
Investors
Investor Relations Events & Presentations Stock Quote & Chart Press Releases Corporate Governance SEC Filings Contact Email Alerts
Contact [email protected] 888.958.1253
Zevra Logo
Footer link Zevra Facebook
Footer link Zevra X twitter
Footer link Zevra linkedin
© 2026 Zevra Therapeutics.
All rights reserved.
|
Privacy Policy
|
Notice at Collection
|
Your Privacy Choices
|
Terms of Use